30% in 2019, cancer drug margins at 700% now

A trade margin is the portion of a medicine’s final maximum retail price that remains with distributors and pharmacies. A mark-up measures the increase added to the stockist’s purchase price. The maximum retail price, or MRP, is the highest listed price a patient should pay at the pharmacy. These measures matter because they describe the same price gap in different ways.

The article gives the key conversion. A 30% trade margin equals a 43% mark-up. That is because the trade margin is calculated as a percentage of the final MRP, while the mark-up is calculated as a percentage of the price paid by the stockist. For example, if the stockist price is 100, a 43% mark-up produces an MRP of 143. The margin is 43 out of 143, or about 30%.

The distinction exposes why a medicine can appear to meet one rule while carrying a very large mark-up. In the NPPA’s 2026 list, many drugs previously covered by the 2019 policy had mark-ups between 100% and more than 700%. Patients therefore need clear, consistently monitored limits, not only occasional MRP reductions.

The latest NPPA price-reduction list covered 137 anti-cancer drugs. Of these, 34 were also included among the 42 anti-cancer drugs named in the NPPA’s 2019 list. The comparison matters because it allows the earlier policy’s results to be tested against later prices. It shows whether the earlier intervention held over time.

The article reports that most of the 34 overlapping drugs had mark-ups above 43% before the latest order. A 43% mark-up is equivalent to a 30% trade margin. The remaining 2019 drugs had even higher mark-ups, ranging from 100% to more than 700%. This indicates that the earlier reduction did not permanently keep price gaps at the intended level.

The latest list therefore represents both a broad intervention and a measure of policy limits. It includes many more medicines than the 2019 list, while revisiting 34 earlier cases. The comparison supports AIDAN’s argument that lasting margin controls and regular monitoring are needed alongside one-time price cuts.

A one-time price order changes the listed MRP at that moment, but it does not automatically freeze the future relationship between the stockist price and the retail price. If companies or sellers later raise the mark-up within an uncontrolled system, the gap can widen again. This is why a medicine can once have been subject to a 30% trade-margin cap yet later show a much larger mark-up.

The article reports that only five brands from the 2019 list had a 43% mark-up before the latest order. Four more had mark-ups between 43% and 100%. The remaining 39 had mark-ups from 100% to over 700%. The 43% threshold represents a 30% trade margin because the two percentages use different bases.

The article attributes the recurrence to the absence of a permanent margin mandate and consistent monitoring. NPPA reduced MRPs again in 2026, but AIDAN says this repeats the earlier pattern. Without continuing oversight, another temporary reduction may again lose its effect as mark-ups rise.

In February 2019, the NPPA placed a 30% trade-margin cap on the selling price for selected anti-cancer medicines. In practical terms, it required a one-time reduction in MRP by restricting the mark-up between the stockist price and the listed retail price. The policy changed prices at that point, rather than establishing an ongoing system that would automatically restrain future mark-ups.

The article’s example is Pemetrexed. One brand’s MRP dropped from Rs 7,000 to Rs 800 in 2019. In the latest reduction, it fell from Rs 1,095 to Rs 297. The second cut was more modest, showing that the earlier intervention had already produced a larger reduction for that brand, but had not prevented later price differences from developing.

AIDAN describes the policy as misleadingly called trade-margin capping because it was only a one-time MRP restriction. The article says no mandate required permanent margin caps with consistent monitoring. Consequently, mark-ups later reached 100% to over 700% for many medicines.

Manufacturers influence the starting price through the MRP they set for a brand and through the price at which medicines reach stockists. Stockists and pharmacies then operate within the trade chain, where the difference between their purchase price and the final MRP becomes the mark-up or trade margin. The patient ultimately encounters the MRP at the pharmacy.

The article explains that a 30% trade margin is measured against the final MRP, while a mark-up is measured against the stockist’s price. That distinction allows the same price structure to look different depending on the calculation. NPPA regulates the system by ordering MRP reductions or imposing stated margin restrictions. The 2019 order did not permanently control later mark-ups.

The 2026 list demonstrates the consequence. Many drugs covered in 2019 later showed mark-ups of 100% to more than 700% before the latest order. Manufacturers, sellers, and regulators therefore affect affordability at different points. Permanent caps and regular checks would make the final price less dependent on occasional intervention.

A permanent margin cap would set a continuing ceiling on the gap between a medicine’s stockist price and its MRP. Regular monitoring would check whether manufacturers and sellers continued to follow that ceiling. Together, these measures would address both the rule and its enforcement. They would differ sharply from a single order that changes the price only once.

The article shows why this matters. After the 2019 intervention, only five brands had a 43% mark-up before the latest order. Four had mark-ups from 43% to 100%, while the remaining 39 ranged from 100% to over 700%. A 43% mark-up corresponds to the earlier 30% trade-margin level. These figures indicate that the earlier price reset did not last.

A permanent system could make reductions more durable and prevent mark-ups from returning to very high levels. It could also reveal problems before another large emergency cut becomes necessary. AIDAN argues that consistent monitoring must accompany permanent caps, because repeated one-time orders provide limited relief.

Cancer medicines are central to this debate because the article focuses on anti-cancer drugs and the consequences of their pricing. It describes the All-India Drug Action Network as working on access to affordable medicines. When prices are high, a one-time reduction may offer important relief, but patients can remain vulnerable if mark-ups later rise again.

The article gives a concrete example. One brand of Pemetrexed had an MRP of Rs 7,000 before falling to Rs 800 in 2019. In the latest order, its MRP fell from Rs 1,095 to Rs 297. It also reports that many other medicines had mark-ups of 100% to more than 700% before the latest reduction.

These figures show why stable pricing matters for patients needing cancer treatment. The article does not provide a general estimate of cancer-treatment costs or describe individual patients’ urgency. It does show that repeated price interventions are being used, while AIDAN calls for permanent margin caps and consistent monitoring to protect affordability.